We evaluated clinical factors such as tumor grade, patient sex, patient age, IDH mutation status, 1p19q mutation status, MGMT promoter (MGMTp) methylation status, immune microenvironment status, and tumor mutation burden (TMB). The gene discussed is MGMT; the disease is neoplasm.